HTG Molecular Diagnostics (HTGM) Files $60M IPO

HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) filed with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $60 million. The company has applied to list its shares on NASDAQ Global Market under the symbol "HTGM".

Leerink Partners is the book-running managers. Canaccord Genuity and JMP Securities are co-managers.

HTG Molecular Diagnostics is a commercial stage company that developed and markets a novel technology platform to facilitate the routine use of complex molecular profiling. The company's HTG Edge automated platform can quickly, robustly and simultaneously profile thousands of clinically relevant molecular targets from samples a fraction of the size required by current technologies. The company's objective is to establish the HTG Edge platform as a standard in molecular profiling and make this capability accessible to all molecular labs from research to the clinic. They believe that its target customers desire high quality molecular profiling information in a multiplexed panel format from increasingly smaller samples, with the ability to do this locally to minimize turnaround time and cost. The HTG Edge platform was designed to meet these needs and is empowering pathologists, clinicians and molecular labs to directly control the molecular profiling of patient samples.

Link to S-1

You May Also Be Interested In